Equities analysts forecast that Immatics (NASDAQ:IMTX) will announce earnings per share of ($0.34) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Immatics’ earnings. The highest EPS estimate is ($0.31) and the lowest is ($0.37). The business is expected to announce its next quarterly earnings report on Tuesday, June 29th.
On average, analysts expect that Immatics will report full year earnings of ($1.51) per share for the current fiscal year, with EPS estimates ranging from ($1.64) to ($1.31). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.74) per share, with EPS estimates ranging from ($2.00) to ($1.51). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Immatics.
Several equities research analysts recently commented on the company. Zacks Investment Research cut Immatics from a “hold” rating to a “sell” rating in a research note on Monday, March 22nd. Chardan Capital restated a “buy” rating on shares of Immatics in a report on Sunday, April 4th. Finally, SVB Leerink upped their target price on shares of Immatics from $17.00 to $26.00 and gave the stock an “outperform” rating in a report on Tuesday, March 23rd. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $19.60.
Shares of NASDAQ:IMTX traded down $0.46 during trading on Tuesday, reaching $11.99. The stock had a trading volume of 165,621 shares, compared to its average volume of 641,543. Immatics has a 52 week low of $8.66 and a 52 week high of $18.42. The firm’s fifty day moving average is $12.32 and its 200 day moving average is $11.08.
Immatics Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Recommended Story: Why do companies pay special dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.